What Researchers Did
Researchers conducted a 10-year randomized controlled trial to assess the efficacy of hyperbaric oxygen therapy on visual function in patients with retinitis pigmentosa.
What They Found
At 5 years, 87.5% of patients receiving hyperbaric oxygen therapy preserved 80% of their initial visual acuity, compared to 70.4% in the control group (p < 0.01). By 10 years, 63.33% of the hyperbaric oxygen group maintained 80% of initial visual acuity, whereas only 40% of the control group did (p = 0.05).
What This Means for Canadian Patients
Canadian patients with retinitis pigmentosa might experience a slower decline in visual acuity with hyperbaric oxygen therapy. This treatment could potentially help preserve vision for a longer period, offering a new therapeutic avenue.
Canadian Relevance
This study was not conducted in Canada and does not have direct Canadian relevance.
Study Limitations
A limitation of this study is its single-center design, which may affect the generalizability of the findings.